Medical device designer, developer, and manufacturer Viveve Medical (NASDAQ: VIVE) has been facing hardship from 2013’s crash and never recovered significantly. Today’s news regarding SUI feasibility study could cause a sudden growth of 40% in premarket on the volume of 4 million shares.
Just any healthcare company, Viveve is still burning cash that comes from taking loans and issuing shares. How long will its EPS stay negative by chasing away long term stockholders? The question itself creates a blurred picture in the profitability of the company since innovative products always require a lot of funds before generating revenues.
The stock is very cheap and could soar further as the next study’s process may come out again. Adding it to the watchlist is the wisest move of daily trading investors.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.